Levetiracetam Hospira

Levetiracetam, the active ingredient in Levetiracetam Hospira, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in patients who require parenteral therapy, and is classified under ATC code N03AX14.

GNH USA supplies Levetiracetam Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with rigorous quality standards and regulatory compliance.

Levetiracetam is an antiepileptic medication that modulates synaptic neurotransmitter release to control seizure activity.

- Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps achieve seizure control in primary generalized seizures. - Myoclonic seizures: decreases myoclonic jerks and improves overall seizure management.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: transient sensation of lightheadedness. - Fatigue: general tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset. - Irritability: mood changes or increased agitation. - Somnolence: drowsiness or sleepiness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering. - Blood dyscrasias: neutropenia or thrombocytopenia. - Mood disturbances: depression or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes. - Respiratory depression: difficulty breathing (rare).

When using Levetiracetam Hospira, clinicians should consider several precautionary measures to ensure safe administration. - Renal impairment: adjust dosing or monitor renal function. - Hepatic dysfunction: evaluate liver status before use. - Pregnancy: category B, use only if benefit outweighs risk. - Concomitant CNS depressants: monitor for enhanced sedation. - Psychiatric history: watch for mood changes or suicidal ideation. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase risk of adverse CNS effects. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Immunosuppressants (e.g., cyclosporine): monitor for altered drug levels. - Oral contraceptives: may have reduced efficacy, advise alternative contraception.